Rlavie Chiral Building Blocks: Market Applications and Portfolio Outlook
Explore Rlavie chiral building blocks for route research, medicinal chemistry and analytical development.
Defined stereochemistry can make a building block more useful to a medicinal-chemistry or process-development team. Rlavie’s portfolio connects specific chiral products with practical research needs: preparing analogues, comparing routes, studying impurities and developing analytical methods.
Choose products by the job they need to do
Bis-THF alcohol (CAS 156928-09-5) is an advanced fragment for public protease-inhibitor route research. Safinamide (CAS 133865-89-1) is listed for pharmaceutical research enquiries. The paired (R)-1,3-dimethylpiperazin-2-one and (S)-1,3-dimethylpiperazin-2-one offer starting points for comparing enantiomers. Functionalized amino-acid derivatives provide azido or iodo handles for further development, while (+)-citronellal and (R)-citronellic acid / (S)-citronellic acid address chiral fine-chemical research.
The product directory below also includes tolterodine-related compounds, a phosphino-oxazoline-containing ligand, and two pairs of oncology-route intermediates. Each product name and CAS number opens its own Rlavie record so that researchers can compare exact identity and stereochemistry before making an enquiry.
Market outlook: value in research efficiency
The commercial proposition is the potential to save upstream synthesis work and improve access to defined structures. FDA stereoisomer guidance supports the importance of understanding and measuring stereochemical composition. ICH Q11 and Q14 provide frameworks for process and analytical development. Together these explain why identity, suitable analytical data and specification alignment matter to buyers; they do not establish a market-size estimate or a particular supplier’s sales growth.
From a catalog enquiry to a defined project
Start with the compound, quantity, intended application and required analytical specifications. Discuss documentation, packaging, availability and custom-synthesis feasibility with Rlavie. Requirements should be agreed for the individual project and batch. Public route relevance does not by itself establish supply to a marketed medicine.
Related Rlavie products
- N-(3-Chloro-4-fluorophenyl)-6-nitro-7-[[(3S)-tetrahydro-3-furanyl]oxy]-4-quinazolinaMine — CAS 314771-88-5
- (S)-N4-(3-chloro-4-fluorophenyl)-7-(tetrahydrofuran-3-yloxy)quinazoline-4,6-diaMine — CAS 314771-76-1
- (S)-1-(2,6-Dichloro-3-fluorophenyl)ethanol — CAS 877397-65-4
- (R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine — CAS 877399-00-3
- (2S,4S)-4-azido-1-[(tert-butoxy)carbonyl]pyrrolidine-2-carboxylic acid — CAS 132622-65-2
- (R)-tert-Butyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-iodopropanoate — CAS 282734-33-2
- (+)-Citronellal — CAS 2385-77-5
- (R)-(+)-Citronellicacid — CAS 18951-85-4
- (S)-(-)-Citronellic acid — CAS 2111-53-7
- (2R)-2-[(4R)-4,5-Dihydro-4-(phenylmethyl)-2-oxazolyl]-1-(diphenylphosphino)piperidine — CAS 2757084-65-2
- (R)-1,3-Dimethyl-piperazin-2-one — CAS 1240300-33-7
- (S)-1,3-Dimethyl-piperazin-2-one — CAS 1240300-34-8
- (R)-5-HydroxyMethyl Tolterodine — CAS 207679-81-0
- Tolterodineacid — CAS 194482-44-5
- Safinamide — CAS 133865-89-1
- (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol — CAS 156928-09-5
Contact Rlavie for specifications and a quotation, or discuss custom synthesis.
Resources and references
- FDA: Development of New Stereoisomeric Drugs
- ICH Q11: process development and control strategy
- ICH Q14: final adopted analytical procedure development guideline
Links and product identities reviewed on 16 September 2026. Application outlook is qualitative; availability, specifications and suitability are confirmed by project enquiry.